News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
The campaign aims to bring back focus on leprosy case detection, treatment and rehabilitation; especially in the context of neglect brought in by Covid-19 pandemic
Key takeaways of recent quarter & conference call highlights
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry
Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice
Takes charge to lead business innovation, strategy, alliance & partnerships
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
